March 1, 2024
News
March 1, 2024
Clinical Trials Arena: Artiva Prepares to Kick off Phase I/II Trial for NK Cell Therapy
February 22, 2024
Artiva Biotherapeutics Receives FDA Fast Track Designation for AlloNK® in Lupus Nephritis
February 21, 2024
GEN: Easier Access to NK-Based Cell Therapies
December 14, 2023
Artiva Named a PM360 2023 Innovative Startup
November 8, 2023
Artiva Biotherapeutics Receives Immunology Innovation of the Year in the 2023 BioTech Breakthrough Awards Program
November 2, 2023
Beyond Biotech Podcast: Natural Killer Cells
August 16, 2023
Artiva Biotherapeutics Announces FDA Clearance of IND for AlloNK® Cell Therapy Candidate in Combination with Rituximab in Lupus Nephritis
May 25, 2023
Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting
April 26, 2023